Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739339 | 0.98 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTSMN1; SMN2CHRM1 | |
| SCHEMBL24512542 | 0.98 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTSMN1; SMN2CHRM1 | |
| SCHEMBL3388901 | 0.96 | GAA (0.41) | ALDH1A1GAAMAPTSMN1; SMN2CHRM1 | |
| SCHEMBL1694342 | 0.92 | GAA (0.44) | ALDH1A1GAAMAPTSMN1; SMN2POLB | |
| SCHEMBL27130827 | 0.84 | GAA (0.42) | ALDH1A1GAAMAPTSMN1; SMN2POLB | |
| SCHEMBL15566866 | 0.84 | ALDH1A1 (0.40) | ALDH1A1GAAMAPTSMN1; SMN2CHRM1 | |
| SCHEMBL27006521 | 0.84 | GAA (0.42) | ALDH1A1GAAMAPTSMN1; SMN2POLB | |
| SCHEMBL16698412 | 0.83 | NAAA (0.41) | ALDH1A1ATMHPGDNAAA | |
| SCHEMBL15535983 | 0.82 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2HSD17B10HPGDNAAA | |
| SCHEMBL15566435 | 0.82 | GAA (0.37) | ALDH1A1GAAMAPTSMN1; SMN2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-14 | — | — | US | disclosed |
| EP-2852575-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | Actelion Pharmaceuticals Ltd. (CH) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013175397-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2009071707-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071707-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-06-11 | — | — | WO | disclosed |
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | ALDH1A1 130/4885GAA 400/4885MAPT 3196/4885 |
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | IMPDH1, IMPDH2, ITPA | ALDH1A1 631/4885GAA 2505/4885MAPT 2071/4885 |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | ALDH1A1 475/4885GAA 76/4885MAPT 3834/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | ALDH1A1 474/4885GAA 572/4885MAPT 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.